RHDv2 is a non-enveloped virus in the Caliciviridae family, which also contains Feline calicivirus and human and murine norovirus. As such, they are fairly resistant to environmental factors and are known to survive for extended periods of time on surfaces and be spread to other animals this way. Under the Emerging Viral Pathogen Guidance, Intervention® meets the criteria to be used against this virus, due to its efficacy against at least two small non-enveloped viruses from a different family.
In cases of emerging viral pathogens like SARS-CoV-2, the virus that causes COVID-19, when there is no test that can be conducted to validate the efficacy of a disinfectant, the EPA utilizes Emerging Viral Pathogen Guidance to determine the expected efficacy of a disinfectant against an emerging virus. This guidance used previously during the 2003 SARS epidemic, mandates that for disinfectant products to be approved, they must be an EPA registered Hospital or Broad-Spectrum disinfectant and have proven efficacy against two small, non-enveloped viruses, such as Poliovirus and Parvovirus.